ID | 1107 | |
PMID | 20223589 | |
Year | 2010 | |
Sequence | ACSSSPSKHCG | |
Name | TD-1 | |
Length | 11 | |
N-Terminal Modification | Free | |
C-Terminal Modification | Free | |
Linear/ Cyclic | Cyclic (C2-C10) | |
Chirality | L | |
Chemical Modification | None | |
Origin of Peptide | De novo synthesis | |
Nature of Peptide/Cargo | TD1 enhances the transdermal delivery of macromolecules | |
Mechanism | TD1 overcomes the skin barrier by a distinct mechanism that most likely involves specific interactions between TD1 and unknown skin components | |
Cargo Sequence/Structure | None | |
Name of cargo | Botulinum neurotoxin type A (BoNT-A) | |
Assay | Electrical stimulation of the saphenous nerve at 4 Hz for 1 min in skin pretreated with vehicle | |
Enhancer | None | |
Properties of enhancer | Not applicable | |
Concentration | 100 µL solution containing 2.5 U BoNT-A and 100 µg TD-1 in 0.9% saline 0.9% saline | |
Incubation time | 3 and 6 h | |
Tissue permeability (value with units) | The maximum amount of PE (Plasma Extravasation) in the control side was 68 ± 3 PIUs compared to 46 ± 2 PIUs in BoNT-A + TD-1 pretreated skin | |
Tissue Sample | Dorsal surface of the rat hindpaw skin | |
Ex vivo/In vivo/In vitro | in vivo | |
STRUCTURE |
| |
SMILES | N[C@@H](C)C(=O)N[C@H]1CSSC[C@H] (NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC (=O)[C@H]2N(C(=O)[C@@H](NC(=O)[C@@H](NC (=O)[C@@H](NC1=O)CO)CO)CO)CCC2)CO) CCCC[NH3])Cc1nc[nH]c1)C(=O)NCC=O |